You are here: Home: Meet The Professors - Breast Cancer 1 | 2009: CME Information

Meet The Professors: A case-based discussion on the management of breast cancer in the adjuvant and metastatic settings

OVERVIEW OF ACTIVITY

Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. To offer optimal patient care — including the option of clinical trial participation — practicing medical oncologists, hematologists and hematology-oncology fellows must be well informed of these advances. Meet The Professors uses relevant case-based discussions between community oncologists and clinical investigators to assist practicing clinicians’ incorporation of this information into their management strategies for breast cancer.

LEARNING OBJECTIVES

• Utilize genomic assays to quantify recurrence risk and aid in the selection of appropriate treatment options.
• Counsel pre- and postmenopausal patients with ER/PR-positive breast cancer about the risks and benefits of adjuvant endocrine therapy, addressing agent sequence and duration of treatment.
• Compare and contrast the safety and efficacy of anthracycline- and nonanthracycline-containing adjuvant regimens when recommending chemotherapy for patients with Stage I to Stage III breast cancer.
• Integrate case-based learning into the selection of treatment strategies for patients with HER2-positive early and advanced breast cancer.
• Assess the clinical activity of established and novel anti-HER2 agents in patients with HER2-positive tumors progressing on trastuzumab.
• Communicate the benefits and risks of neoadjuvant systemic therapy to patients with locally advanced breast cancer.
• Appraise the implications of occult axillary lymph node metastases on breast cancer prognosis and the selection of adjuvant systemic therapy.
• Apply the results of emerging research to effectively and safely integrate bevacizumab into the front-line treatment of metastatic breast cancer.
• Counsel appropriately selected patients about participation in ongoing clinical trials.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this educational activity for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

HOW TO USE THIS CME ACTIVITY

This CME activity contains audio, print and web components. To receive credit, the participant should review the CME information, listen to the CDs and complete the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/MTP/Breast.

This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech BioOncology and Genomic Health Inc.